Fig. 3: Subgroup analysis of PFS in patients with a bTMB ≥16. | Nature Medicine

Fig. 3: Subgroup analysis of PFS in patients with a bTMB ≥16.

From: Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Fig. 3

a, Forest plot of subgroups. Error bars, 95% CI. b,c, PFS Kaplan–Meier curves for the nonsquamous (b) and squamous (c) subgroups. Atezo, atezolizumab; Chemo, chemotherapy; lxRS, interactive voice/web response system; NA, not analyzed; NE, not estimable.

Back to article page